{
    "paper_id": "eb68989d94257ec4c319dd1d364300d57e5e452e",
    "metadata": {
        "title": "Journal Pre-proof Compensation de la dose totale en cas d'interruption temporaire de radioth\u00e9rapie externe dans le contexte de la pand\u00e9mie de COVID-19 : mise au point pratique Practical update of total dose compensation in case of temporary interruption of external radiotherapy in the COVID-19 pandemic context",
        "authors": [
            {
                "first": "David",
                "middle": [],
                "last": "Azria",
                "suffix": "",
                "affiliation": {
                    "laboratory": "IRCM",
                    "institution": "",
                    "location": {
                        "addrLine": "208, avenue des Apothicaires",
                        "postCode": "34298, cedex 5",
                        "settlement": "Montpellier",
                        "country": "France"
                    }
                },
                "email": ":david.azria@icm.unicancer.fr"
            },
            {
                "first": "Christophe",
                "middle": [],
                "last": "Hennequin",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Service de canc\u00e9rologie-radioth\u00e9rapie",
                    "institution": "AP-HP, h\u00f4pital Saint-Louis",
                    "location": {
                        "addrLine": "1, avenue Claude-Vellefaux",
                        "postCode": "75475",
                        "settlement": "Paris",
                        "country": "France"
                    }
                },
                "email": ""
            },
            {
                "first": "Philippe",
                "middle": [],
                "last": "Giraud",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Service d'oncologie radioth\u00e9rapie",
                    "institution": "AP-HP, h\u00f4pital europ\u00e9en Georges-Pompidou",
                    "location": {
                        "addrLine": "20, rue Leblanc",
                        "postCode": "75015",
                        "settlement": "Paris",
                        "country": "France"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "L'\u00e9talement est un facteur important de r\u00e9cidive locale et indirectement d'\u00e9volution \u00e0 distance, notamment en cas de dur\u00e9e de traitement allong\u00e9e. La pand\u00e9mie actuelle a un impact sur les patients en cours de radioth\u00e9rapie qui doivent interrompre leur traitement de mani\u00e8re parfois prolong\u00e9e du fait de la n\u00e9cessit\u00e9 de soins respiratoires induits par le COVID-19. Les mod\u00e8les utilis\u00e9s de compensation de la dose totale en cas d'interruption prolong\u00e9e de la radioth\u00e9rapie sont connus, mais il nous a sembl\u00e9 important de synth\u00e9tiser afin que chaque oncologue radioth\u00e9rapeute puisse proposer un traitement le plus optimal possible tant en termes de risque de r\u00e9cidive locale que de protection des tissus sains. L'objectif de ce type de recommandation est d'homog\u00e9n\u00e9iser les pratiques de l'ensemble de la discipline.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Overall treatment time is an important factor of local recurrence and indirectly of distant evolution, namely in case of protracted treatments. The current pandemic impacts on the duration of radiotherapy if patients under treatments and synchronously suffering from COVID-19. The models used to compensate the total dose in case of temporary treatment interruption are well known but it Page 2 of 13 J o u r n a l P r e -p r o o f 2 is of importance in that pandemic context to update and homogenize clinical practice in order to improve local control without increasing normal tissue complications.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "L'\u00e9talement est un facteur important de r\u00e9cidive locale et indirectement d'\u00e9volution \u00e0 distance, notamment en cas de dur\u00e9e de traitement allong\u00e9e. La pand\u00e9mie actuelle a un impact sur les patients en cours de radioth\u00e9rapie qui doivent interrompre leur traitement de mani\u00e8re parfois prolong\u00e9e du fait de la n\u00e9cessit\u00e9 de soins respiratoires induits par le COVID-19. Les mod\u00e8les utilis\u00e9s de compensation de la dose totale en cas d'interruption prolong\u00e9e de la radioth\u00e9rapie sont connus, mais il nous a sembl\u00e9 important de synth\u00e9tiser afin que chaque oncologue radioth\u00e9rapeute puisse proposer un traitement le plus optimal possible tant en termes de risque de r\u00e9cidive locale que de protection des tissus sains. L'objectif de ce type de recommandation est d'homog\u00e9n\u00e9iser les pratiques de l'ensemble de la discipline.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "R\u00e9sum\u00e9"
        },
        {
            "text": "Dose totale ; compensation ; radioth\u00e9rapie ; \u00e9talement",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Mots cl\u00e9s"
        },
        {
            "text": "Overall treatment time is an important factor of local recurrence and indirectly of distant evolution, namely in case of protracted treatments. The current pandemic impacts on the duration of radiotherapy if patients under treatments and synchronously suffering from COVID-19. The models used to compensate the total dose in case of temporary treatment interruption are well known but it is of importance in that pandemic context to update and homogenize clinical practice in order to improve local control without increasing normal tissue complications. Keywords: Total dose; treatment duration; radiotherapy; compensation 1. Introduction L'\u00e9talement est le param\u00e8tre radiobiologique qui correspond \u00e0 la dur\u00e9e totale du traitement (intervalle de temps entre la premi\u00e8re et la derni\u00e8re s\u00e9ance de radioth\u00e9rapie). Ce param\u00e8tre est un facteur important de r\u00e9cidive locale et indirectement d'\u00e9volution \u00e0 distance notamment en cas de dur\u00e9e de traitement allong\u00e9e [1] .",
            "cite_spans": [
                {
                    "start": 958,
                    "end": 961,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Les causes de protraction th\u00e9rapeutique peuvent \u00eatre nombreuses et les plus fr\u00e9quemment rencontr\u00e9es (effets secondaires aigus, panne d'un acc\u00e9l\u00e9rateur, pont de jours f\u00e9ri\u00e9s, etc.) ne n\u00e9cessitent pas de compensation de dose \u00e9tant donn\u00e9 la bri\u00e8vet\u00e9 des interruptions, souvent moins de 3 ou 4 jours.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Jusqu'\u00e0 r\u00e9cemment, certains rares effets secondaires aigus tr\u00e8s s\u00e9v\u00e8res [2] ou une raison inattendue et exceptionnelle d'arr\u00eat de la radioth\u00e9rapie n\u00e9cessitaient des interruptions parfois longues et posaient la question d'une \u00e9quivalence de dose lorsque l'arr\u00eat d\u00e9passait 8 jours.",
            "cite_spans": [
                {
                    "start": 72,
                    "end": 75,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                }
            ],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Le 11 mars 2020, le directeur g\u00e9n\u00e9ral de l'Organisation mondiale de la sant\u00e9 (OMS) a \u00e9lev\u00e9 l'infection \u00e0 SARS-CoV-2 (virus responsable du COVID-19) \u00e0 un niveau pand\u00e9mique, avec une \u00e9volution exponentielle jusqu'\u00e0 ce jour du nombre de cas, soit environ 1 300 000 personnes d\u00e9clar\u00e9es comme contamin\u00e9es dans 179 pays du monde et plus de 66 000 morts. Malheureusement, certains patients actuellement en cours de radioth\u00e9rapie pour le traitement de leur cancer sont infect\u00e9s par le virus, ce qui les contraint \u00e0 interrompre temporairement leur radioth\u00e9rapie pour une dur\u00e9e variable en fonction des sympt\u00f4mes propres \u00e0 l'infection virale. Certains n\u00e9cessitent une prise en charge plus importante avec un arr\u00eat de pr\u00e8s de 1 mois, voire plus en cas d'assistance respiratoire prolong\u00e9e.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Dans cet article, nous d\u00e9taillons les mod\u00e8les connus de compensation de la dose totale en cas d'interruption prolong\u00e9e de la radioth\u00e9rapie avec une approche pratique en fonction des localisations tumorales trait\u00e9es [3] . Cet article a \u00e9t\u00e9 \u00e9crit avec l'objectif d'aider les oncologues radioth\u00e9rapeutes et les physiciens m\u00e9dicaux \u00e0 calculer les doses n\u00e9cessaires \u00e9quivalentes notamment pour les patients qui vont rapidement revenir en radioth\u00e9rapie apr\u00e8s leur traitement sp\u00e9cifique du COVID-19. Plus g\u00e9n\u00e9ralement, il peut s'appliquer \u00e0 la prise en charge sp\u00e9cifique en cas de d\u00e9sastres, qui malheureusement, peuvent \u00e0 nouveau survenir [4] .",
            "cite_spans": [
                {
                    "start": 215,
                    "end": 218,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 633,
                    "end": 636,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                }
            ],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "De nombreuses \u00e9tudes ont montr\u00e9 que la protraction du traitement pouvait entrainer une perte de 1 \u00e0 2% du taux de contr\u00f4le local par jour de prolongation de la dur\u00e9e de traitement en cas de fractionnement classique de 2 Gy par jour et 5 jours par semaine. Ces \u00e9l\u00e9ments sont d'autant plus critiques dans les cancers \u00e0 division cellulaire rapide, comme ceux du col ut\u00e9rin, de la t\u00eate et du cou et du poumon [1, 5] .",
            "cite_spans": [
                {
                    "start": 405,
                    "end": 408,
                    "text": "[1,",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 409,
                    "end": 411,
                    "text": "5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9talement, d\u00e9lai de prolongation, repopulation tumorale"
        },
        {
            "text": "La dose totale requise pour l'obtention d'une r\u00e9ponse tumorale donn\u00e9e (correspondant g\u00e9n\u00e9ralement \u00e0 la probabilit\u00e9 du contr\u00f4le de 50% de la tumeur, TCP50, par une radioth\u00e9rapie d\u00e9livr\u00e9e \u00e0 une dose quotidienne de 2 Gy) varie en fonction de la dur\u00e9e du traitement [3] . La limite au-del\u00e0 de laquelle, cette dose totale d\u00e9pend de l'\u00e9talement est d\u00e9finie par le d\u00e9lai de prolongation.",
            "cite_spans": [
                {
                    "start": 262,
                    "end": 265,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9talement, d\u00e9lai de prolongation, repopulation tumorale"
        },
        {
            "text": "Le d\u00e9lai de prolongation correspond au temps \u00e9coul\u00e9 entre le premier jour du traitement et le d\u00e9but th\u00e9orique de la repopulation [6] .",
            "cite_spans": [
                {
                    "start": 129,
                    "end": 132,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9talement, d\u00e9lai de prolongation, repopulation tumorale"
        },
        {
            "text": "Dans un \u00e9talement initialement programm\u00e9 inf\u00e9rieur au d\u00e9lai de prolongation, cette dose totale ne d\u00e9pend pas du temps car dans cet intervalle il existe une faible (voire une absence de) repopulation tumorale pendant le traitement. En revanche, d\u00e8s que la dur\u00e9e de traitement augmente significativement, la dose totale n\u00e9cessaire au contr\u00f4le tumoral (TCP50) devient d\u00e9pendante du temps, en rapport avec la capacit\u00e9 de la tumeur \u00e0 se diviser. Une majoration de la dose totale devient alors n\u00e9cessaire afin de compenser cette repopulation tumorale.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "\u00c9talement, d\u00e9lai de prolongation, repopulation tumorale"
        },
        {
            "text": "En pratique, si une interruption d'une dur\u00e9e \u00ab t \u00bb est survenue dans l'intervalle de temps initialement pr\u00e9vu de traitement \u00ab T \u00bb, la dur\u00e9e d'allongement du traitement sera exactement de dur\u00e9e \u00ab t \u00bb mais avec une dose de compensation sup\u00e9rieure \u00e0 la dose totale initialement pr\u00e9vue, \u00e0 condition de contr\u00f4ler la tol\u00e9rance sur les tissus sains environnants.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "\u00c9talement, d\u00e9lai de prolongation, repopulation tumorale"
        },
        {
            "text": "Cette notion d'\u00ab extra-dose \u00bb est n\u00e9cessaire car le traitement est souvent repris dans la p\u00e9riode de repopulation avec une iso-TCP50 n\u00e9cessairement sup\u00e9rieure. Cela est valable si le fractionnement classique est maintenu et que la reprise de la radioth\u00e9rapie n'inclut pas de s\u00e9ance le week-end et/ou n'utilise pas un hyperfractionnement quotidien.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "\u00c9talement, d\u00e9lai de prolongation, repopulation tumorale"
        },
        {
            "text": "La formule classique du calcul de la dose biologique \u00e9quivalente (DBE) d'une irradiation homog\u00e8ne dans un tissu en monofractionnement de 1,8 \u00e0 2 Gy par s\u00e9ance et par jour et incluant la repopulation tumorale potentielle d\u00e9pend de trois grands facteurs : Le facteur d'efficacit\u00e9 relative correspond \u00e0 l'incr\u00e9mentation de la dose par fraction ajust\u00e9 au facteur de fractionnement \u03b1/\u03b2 (en Gy) :",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comment calculer la dose \u00e9quivalente n\u00e9cessaire ?"
        },
        {
            "text": "Le facteur de repopulation correspond au produit de la dose biologique par jour pour compenser la repopulation cellulaire tumorale (K, exprim\u00e9 en grays par jour) par la diff\u00e9rence entre la dur\u00e9e totale du traitement initialement pr\u00e9vue (T) et le d\u00e9lai de prolongation (Tprolong) :",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comment calculer la dose \u00e9quivalente n\u00e9cessaire ?"
        },
        {
            "text": "La formule d\u00e9velopp\u00e9e de la dose biologique \u00e9quivalent devient ainsi :",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comment calculer la dose \u00e9quivalente n\u00e9cessaire ?"
        },
        {
            "text": "Les param\u00e8tres K, Tprolong et \u03b1/\u03b2 sont sp\u00e9cifiques du tissu.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comment calculer la dose \u00e9quivalente n\u00e9cessaire ?"
        },
        {
            "text": "En aucun cas, la dose \u00e9quivalente n\u00e9cessaire ne se calcule en rajoutant des s\u00e9ances suppl\u00e9mentaires \u00e0 la fin du traitement. Cette m\u00e9thode semble pragmatique mais n'est valid\u00e9e dans aucun mod\u00e8le radiobiologique.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comment calculer la dose \u00e9quivalente n\u00e9cessaire ?"
        },
        {
            "text": "Cette formule peut \u00eatre utilis\u00e9e pour le calcul de la dose biologique \u00e9quivalente d\u00e9livr\u00e9e aussi bien aux tissus sains qu'aux tissus tumoraux.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comment utiliser la formule de calcul de la dose biologique \u00e9quivalente en pratique ?"
        },
        {
            "text": "Pour les tissus sains \u00e0 r\u00e9ponse tardive (g\u00e9n\u00e9ralement facteurs importants des s\u00e9quelles \u00e0 long terme), le taux de prolif\u00e9ration tissulaire est tr\u00e8s faible, permettant de n\u00e9gliger le facteur K (en dehors d'une situation de toxicit\u00e9 aigu\u00eb s\u00e9v\u00e8re avec cons\u00e9quences irr\u00e9versibles \u00e0 long terme).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Tissus sains \u00e0 r\u00e9ponse tardive"
        },
        {
            "text": "La formule g\u00e9n\u00e9rale devient alors, avec K = 0 et donc FR = 0 :",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Tissus sains \u00e0 r\u00e9ponse tardive"
        },
        {
            "text": "Il est g\u00e9n\u00e9ralement accept\u00e9 de prendre une valeur de 3 pour le rapport \u03b1/\u03b2 avec quelques variantes pour le cerveau et la moelle \u00e9pini\u00e8re (\u03b1/\u03b2 = 2 Gy). En outre, lorsque l'on estime que la tol\u00e9rance aigu\u00eb des tissus sains risque d'\u00eatre difficile, notamment en cas de n\u00e9cessit\u00e9 d' \u00ab extra-dose \u00bb sur la tumeur, une r\u00e9duction \u00e0 2,5 du rapport \u03b1/\u03b2 semble n\u00e9cessaire.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Tissus sains \u00e0 r\u00e9ponse tardive"
        },
        {
            "text": "Pour les tissus tumoraux, la formule g\u00e9n\u00e9rale est celle d\u00e9crite dans le paragraphe pr\u00e9c\u00e9dent incluant tous les facteurs, notamment ceux repr\u00e9sentatifs du temps et de la repopulation potentielle (K, T et Tprolong) :",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Tissus tumoraux"
        },
        {
            "text": "Lorsqu'une interruption temporaire de traitement a \u00e9t\u00e9 n\u00e9cessaire, les \u00e9tapes de calcul de la compensation de la dose totale doivent \u00eatre r\u00e9alis\u00e9es en respectant les \u00e9tapes suivantes : Il est de la responsabilit\u00e9 de l'oncologue radioth\u00e9rapeute, pour un patient donn\u00e9, de juger si ces modifications du fractionnement/dose totale sont justifi\u00e9es.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Application pratique"
        },
        {
            "text": "Les cancers d\u00e9taill\u00e9s ci-dessous sont ceux pour lesquels les param\u00e8tres radiobiologiques ont \u00e9t\u00e9 publi\u00e9s, notamment K et Tprolong. Un exemple d\u00e9taill\u00e9 de calcul pratique est pr\u00e9sent\u00e9 pour les cancers des voies a\u00e9rodigestives sup\u00e9rieures.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Situations cliniques et diverses valeurs de r\u00e9f\u00e9rences"
        },
        {
            "text": "Il s'agit de la localisation pour laquelle nous disposons du plus grand nombre de donn\u00e9es. L'augmentation de l'\u00e9talement se traduit par une perte de taux de contr\u00f4le local de 2 \u00e0 14% par semaine d'interruption [7] . Globalement, il serait n\u00e9cessaire de d\u00e9livrer une dose suppl\u00e9mentaire de 0,4 \u00e0 0,8 Gy/j perdu. Plus pr\u00e9cis\u00e9ment, le calcul qui peut \u00eatre fait est le suivant :",
            "cite_spans": [
                {
                    "start": 210,
                    "end": 213,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": "Cancers des voies a\u00e9rodigestives sup\u00e9rieures"
        },
        {
            "text": "Param\u00e8tres radiobiologiques pour les cancers des voies a\u00e9rodigestives sup\u00e9rieures [3, 8] \uf0b7 pour les tissus sains \u00e0 r\u00e9ponse tardive : \u03b1/\u03b2 = 3 Gy ;",
            "cite_spans": [
                {
                    "start": 82,
                    "end": 85,
                    "text": "[3,",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 86,
                    "end": 88,
                    "text": "8]",
                    "ref_id": "BIBREF7"
                }
            ],
            "ref_spans": [],
            "section": "Cancers des voies a\u00e9rodigestives sup\u00e9rieures"
        },
        {
            "text": "\uf0b7 pour la tumeur : K = 0,9 Gy/j ; Tprolong = 28 j ; \u03b1/\u03b2 = 10 Gy. Si le traitement est, par exemple, interrompu la quatri\u00e8me semaine pendant 2 semaines et que la reprise de traitement est pr\u00e9vue selon les m\u00eames modalit\u00e9s, soit cinq fractions de 2 Gy, 5 jours par semaine :",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancers des voies a\u00e9rodigestives sup\u00e9rieures"
        },
        {
            "text": "\uf0b7 le temps de traitement sera en tout allong\u00e9 de 14 jours par rapport \u00e0 l'\u00e9talement th\u00e9orique ;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancers des voies a\u00e9rodigestives sup\u00e9rieures"
        },
        {
            "text": "\uf0b7 avec une valeur de K de 0,9 Gy/j, la DBE10 sera plus faible de 0,9 \u00d7 14 = 12,6 Gy10",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancers des voies a\u00e9rodigestives sup\u00e9rieures"
        },
        {
            "text": "La DBE10 requise de compensation est \u00e9gale \u00e0 la DBE10 avant l'interruption plus la DBE10 apr\u00e8s l'interruption moins le facteur de repopulation tumorale : Ce compromis tumeur/tissus sains est essentiel \u00e0 bien prendre en compte lors de la nouvelle dosim\u00e9trie afin d'\u00e9viter des s\u00e9quelles trop importantes. Une diminution de la dose par fraction apr\u00e8s l'interruption sur la tumeur sera alors \u00e0 d\u00e9cider par l'oncologue radioth\u00e9rapeute si le risque de s\u00e9quelles semble inacceptable.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancers des voies a\u00e9rodigestives sup\u00e9rieures"
        },
        {
            "text": "Le plus souvent, la dose par fraction de compensation doit \u00eatre limit\u00e9e \u00e0 2,25 Gy afin d'obtenir une dose correspondante aux tissus sains acceptable d'\u00e9quivalent de 128,75 Gy3.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancers des voies a\u00e9rodigestives sup\u00e9rieures"
        },
        {
            "text": "Les param\u00e8tres radiobiologiques pour les cancers du poumon non \u00e0 petites cellules ont \u00e9t\u00e9 publi\u00e9s [5, 8] . L'impact de l'\u00e9talement dans les cancers bronchiques a \u00e9t\u00e9 clairement mis en \u00e9vidence en cas de radioth\u00e9rapie exclusive, mais aussi dans le cadre des associations de chimioradioth\u00e9rapie concomitante [9, 10] . L'analyse des donn\u00e9es du Radiation Therapy Oncology Group (RTOG) sugg\u00e8re une perte de 2% des taux de survie globale par jour de traitement perdu [11] . L'importance de l'\u00e9talement est encore plus nette dans les cancers bronchiques \u00e0 petites cellules [12] . Les donn\u00e9es concernant les param\u00e8tres tumoraux sont cependant moins homog\u00e8nes que celles des cancers ORL. Classiquement, le rapport \uf061\uf02f\uf062 du cancer bronchique \u00e0 petites cellules \u00e9tait consid\u00e9r\u00e9 aux alentours de 10 Gy [13] . Plus r\u00e9cemment, des donn\u00e9es issues de s\u00e9ries de chimioradioth\u00e9rapie font \u00e9tat d'un rapport \uf061\uf02f\uf062 plus faible, de l'ordre de 4 Gy (mais avec un facteur K de 0,38 Gy/j) [14] . Des donn\u00e9es r\u00e9centes issues de la radioth\u00e9rapie st\u00e9r\u00e9otaxique retrouvent plut\u00f4t un \uf061\uf02f\uf062 de 12 \u00e0 16 Gy [15] .",
            "cite_spans": [
                {
                    "start": 98,
                    "end": 101,
                    "text": "[5,",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 102,
                    "end": 104,
                    "text": "8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 306,
                    "end": 309,
                    "text": "[9,",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 310,
                    "end": 313,
                    "text": "10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 461,
                    "end": 465,
                    "text": "[11]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 566,
                    "end": 570,
                    "text": "[12]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 788,
                    "end": 792,
                    "text": "[13]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 960,
                    "end": 964,
                    "text": "[14]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 1068,
                    "end": 1072,
                    "text": "[15]",
                    "ref_id": "BIBREF14"
                }
            ],
            "ref_spans": [],
            "section": "Cancer du poumon non \u00e0 petites cellules"
        },
        {
            "text": "Param\u00e8tres radiobiologiques pour les cancers du poumon non \u00e0 petites cellules \uf0b7 pour les tissus sains \u00e0 r\u00e9ponse tardive : \u03b1/\u03b2 = 3 Gy ;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancer du poumon non \u00e0 petites cellules"
        },
        {
            "text": "\uf0b7 pour la tumeur : K = 0,5 Gy/j ; Tprolong estim\u00e9 \u00e0 28 jours ; \u03b1/\u03b2 estim\u00e9 \u00e0 8 Gy .",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancer du poumon non \u00e0 petites cellules"
        },
        {
            "text": "Les param\u00e8tres radiobiologiques pour les cancers du col ut\u00e9rin ont \u00e9t\u00e9 publi\u00e9s [8, 16] . L'impact de la dur\u00e9e totale du traitement est majeur pour ces cancers [17] . Cela a \u00e9t\u00e9 confirm\u00e9 dans le cadre des associations de chimioradioth\u00e9rapie concomitante, avec une dur\u00e9e optimale inf\u00e9rieure \u00e0 56 jours [18] .",
            "cite_spans": [
                {
                    "start": 79,
                    "end": 82,
                    "text": "[8,",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 83,
                    "end": 86,
                    "text": "16]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 159,
                    "end": 163,
                    "text": "[17]",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 300,
                    "end": 304,
                    "text": "[18]",
                    "ref_id": "BIBREF17"
                }
            ],
            "ref_spans": [],
            "section": "Cancer du col ut\u00e9rin"
        },
        {
            "text": "Param\u00e8tres radiobiologiques pour les cancers du col ut\u00e9rin \uf0b7 pour les tissus sains \u00e0 r\u00e9ponse tardive \u03b1/\u03b2 = 3 Gy ;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancer du col ut\u00e9rin"
        },
        {
            "text": "\uf0b7 pour la tumeur : K estim\u00e9 \u00e0 0,8 Gy/jour; Tprolong estim\u00e9 \u00e0 28 jours ; \u03b1/\u03b2 estim\u00e9 \u00e0 10 Gy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancer du col ut\u00e9rin"
        },
        {
            "text": "Les param\u00e8tres radiobiologiques pour les cancers du sein ont \u00e9t\u00e9 publi\u00e9s [8, 19] . Il faut d'embl\u00e9e souligner la grande h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 des cancers du sein, de la tumeur de type luminal A de la patiente \u00e2g\u00e9e \u00e0 la mastite carcinomateuse triple-n\u00e9gative de la femme jeune. Il appara\u00eet alors difficile de d\u00e9finir des param\u00e8tres radiobiologiques pour chaque patiente. Ainsi, les calculs issus des donn\u00e9es des s\u00e9ries d'hypofractionnement font \u00e9tat d'un rapport \uf061\uf02f\uf062 aux alentours de 4 Gy ; mais la plupart des patientes incluses dans ces essais avait des tumeurs de petite taille hormonosensibles [20] . Par ailleurs, qu'en est-il de la repopulation tumorale en post-op\u00e9ratoire, dans un environnement tr\u00e8s modifi\u00e9 par rapport aux mod\u00e8les de tumeurs en place. Enfin, l'effet des traitements hormonaux et du trastuzumab sur la progression tumorale est bien d\u00e9montr\u00e9 et pourrait annuler le facteur prolif\u00e9ratif dans nos \u00e9quations. Un autre param\u00e8tre \u00e0 prendre en compte est le d\u00e9lai entre la chirurgie et le d\u00e9but de la radioth\u00e9rapie ; l\u00e0 encore, les donn\u00e9es sont discordantes. Classiquement, il doit \u00eatre inf\u00e9rieur \u00e0 12 semaines [21] . Cependant ces donn\u00e9es sont anciennes, et ne prenaient pas en compte la biologie de la tumeur et la qualit\u00e9 des marges chirurgicales (tr\u00e8s probablement inf\u00e9rieures \u00e0 celles r\u00e9clam\u00e9e aujourd'hui). Il est important de savoir que m\u00eame si la radioth\u00e9rapie a \u00e9t\u00e9 retard\u00e9e de plusieurs mois, elle am\u00e9liore la survie, que ce soit apr\u00e8s une mastectomie ou un traitement conservateur [22] . Donc, quand elle est indiqu\u00e9e, la radioth\u00e9rapie doit \u00eatre faite, m\u00eame 12 mois apr\u00e8s la chirurgie.",
            "cite_spans": [
                {
                    "start": 73,
                    "end": 76,
                    "text": "[8,",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 77,
                    "end": 80,
                    "text": "19]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 589,
                    "end": 593,
                    "text": "[20]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 1119,
                    "end": 1123,
                    "text": "[21]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1500,
                    "end": 1504,
                    "text": "[22]",
                    "ref_id": "BIBREF21"
                }
            ],
            "ref_spans": [],
            "section": "Cancer du sein"
        },
        {
            "text": "Les param\u00e8tres radiobiologiques suivants peuvent \u00eatre propos\u00e9s pour les cancers du sein :",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancer du sein"
        },
        {
            "text": "\uf0b7 pour les tissus sains \u00e0 r\u00e9ponse tardive \u03b1/\u03b2 = 3 Gy ;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancer du sein"
        },
        {
            "text": "\uf0b7 pour la tumeur : K estim\u00e9 \u00e0 0,3 Gy/jour ; Tprolong estim\u00e9 \u00e0 35 jours ; \u03b1/\u03b2 estim\u00e9 \u00e0 4 Gy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancer du sein"
        },
        {
            "text": "Il faut cependant souligner, que dans le contexte de la pand\u00e9mie de COVID-19, les patientes atteintes d'un cancer du sein sous hormonoth\u00e9rapie sont d'excellentes candidates \u00e0 un traitement diff\u00e9r\u00e9 \u00e0 la fin du confinement. Une \u00e9tude fran\u00e7aise avait montr\u00e9, en effet que l'hormonoth\u00e9rapie annulait l'effet du d\u00e9lai apr\u00e8s la chirurgie [23] . En outre, il s'agit souvent de patientes \u00e2g\u00e9es, \u00e0 risque de forme grave de COVID-19, \u00e0 qui il faut \u00e9viter au maximum le risque de contagion. L'hormonoth\u00e9rapie, que ce soit par inhibiteurs de l'aromatase ou par tamoxif\u00e8ne peut tr\u00e8s bien \u00eatre d\u00e9but\u00e9e avant l'irradiation et poursuivant pendant celle-ci [24] [25] [26] .",
            "cite_spans": [
                {
                    "start": 332,
                    "end": 336,
                    "text": "[23]",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 640,
                    "end": 644,
                    "text": "[24]",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 645,
                    "end": 649,
                    "text": "[25]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 650,
                    "end": 654,
                    "text": "[26]",
                    "ref_id": "BIBREF25"
                }
            ],
            "ref_spans": [],
            "section": "Cancer du sein"
        },
        {
            "text": "Les param\u00e8tres radiobiologiques pour les cancers de la prostate ont \u00e9t\u00e9 publi\u00e9s [8, 27] . L'impact de l'\u00e9talement sur le contr\u00f4le du cancer de prostate est tr\u00e8s discut\u00e9 [28] . Certaines \u00e9tudes r\u00e9centes, bas\u00e9es sur des patients trait\u00e9s avec des doses sup\u00e9rieures ou \u00e9gales \u00e0 70 Gy, ne retrouvent aucun effet de la dur\u00e9e totale de traitement sur tous les param\u00e8tres consid\u00e9r\u00e9s (contr\u00f4le local, survie sans m\u00e9tastases, survie sp\u00e9cifique, survie globale) [29] . A contrario, dans une \u00e9tude plus ancienne, Thames et al. ont retrouv\u00e9 un effet d\u00e9l\u00e9t\u00e8re de l'\u00e9talement, et en particulier, paradoxalement, chez les patients \u00e0 faible risque [30] .",
            "cite_spans": [
                {
                    "start": 80,
                    "end": 83,
                    "text": "[8,",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 84,
                    "end": 87,
                    "text": "27]",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 169,
                    "end": 173,
                    "text": "[28]",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 451,
                    "end": 455,
                    "text": "[29]",
                    "ref_id": "BIBREF28"
                },
                {
                    "start": 631,
                    "end": 635,
                    "text": "[30]",
                    "ref_id": "BIBREF29"
                }
            ],
            "ref_spans": [],
            "section": "Cancer de la prostate"
        },
        {
            "text": "\u00c0 partir de cette \u00e9tude, on peut d\u00e9duire les param\u00e8tres radiobiologiques suivants pour les cancers de la prostate :",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancer de la prostate"
        },
        {
            "text": "\uf0b7 pour les tissus sains \u00e0 r\u00e9ponse tardive : \u03b1/\u03b2 = 3 Gy ;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancer de la prostate"
        },
        {
            "text": "\uf0b7 pour la tumeur : K estim\u00e9 \u00e0 0,2 Gy/jour ; Tprolong estim\u00e9 \u00e0 40 jours ; \u03b1/\u03b2 estim\u00e9 \u00e0 4 Gy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancer de la prostate"
        },
        {
            "text": "Cependant, toutes ces \u00e9tudes n'ont pas pris en compte l'hormonoth\u00e9rapie associ\u00e9e, qui met totalement au repos, chez les patients qui ne sont pas r\u00e9sistants \u00e0 la castration, les cellules tumorales. Dans ces conditions, le traitement de ces patients peut \u00eatre d\u00e9cal\u00e9 sans impact sur l'efficacit\u00e9 du traitement. L\u00e0 encore, il s'agit de patients le plus souvent \u00e2g\u00e9s, \u00e0 haut risque de forme grave de la maladie virale.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancer de la prostate"
        },
        {
            "text": "Pour les stades favorables (ISUP1), la surveillance active reste le choix th\u00e9rapeutique premier. Pour les stades interm\u00e9diaires de pronostic favorable (ISUP 2), d\u00e9caler le traitement de quelques semaines appara\u00eet une solution raisonnable. Enfin, pour les autres patients qui n\u00e9cessitent une suppression androg\u00e9nique, celle-ci doit \u00eatre d\u00e9but\u00e9e et la radioth\u00e9rapie d\u00e9cal\u00e9e \u00e0 la fin du confinement.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cancer de la prostate"
        },
        {
            "text": "En ce qui concerne les autres maladies, les facteurs ne sont pas connus ou peu d'\u00e9l\u00e9ments sont disponibles. Quoi qu'il en soit, les oncologues radioth\u00e9rapeutes doivent s'efforcer de recalculer les doses de compensation pour au moins certaines tumeurs tr\u00e8s sensibles \u00e0 l'\u00e9talement incluant les cancers ORL, du poumon, du col ut\u00e9rin, de l'oesophage, du canal anal, cancers de la peau, cancers de la vulve et du vagin, m\u00e9dulloblastome et les tumeurs neuroectodermiques primitives (PNET), les tumeurs connues comme ayant une prolif\u00e9ration \u00e9lev\u00e9e [31] .",
            "cite_spans": [
                {
                    "start": 542,
                    "end": 546,
                    "text": "[31]",
                    "ref_id": "BIBREF30"
                }
            ],
            "ref_spans": [],
            "section": "Autres tumeurs et conclusions"
        },
        {
            "text": "Lorsque les param\u00e8tres radiobiologiques ne sont pas connus pour appliquer les formules math\u00e9matiques, il est acquis de compenser la dose par fraction de 0,25 Gy lors des fractions restantes \u00e0 condition que la reprise soit effectu\u00e9e en sch\u00e9ma classique d'une s\u00e9ance par jour, 5 jours par semaine. En outre, il importe d'\u00e9valuer pr\u00e9cis\u00e9ment l'impact de cette \u00ab extradose \u00bb tumorale sur les tissus sains comme d\u00e9taill\u00e9 pr\u00e9c\u00e9demment. L'enjeu du contr\u00f4le local est majeur permettant le plus souvent une am\u00e9lioration de la quantit\u00e9 de vie, mais il faut \u00e9viter le plus possible des s\u00e9quelles graves irr\u00e9versibles et donc une qualit\u00e9 de vie tr\u00e8s r\u00e9duite.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Autres tumeurs et conclusions"
        },
        {
            "text": "Ces propositions ne concernent bien entendu que les sch\u00e9mas de radioth\u00e9rapie normofractionn\u00e9s (1,8 \u00e0 2 Gy par fraction, une fraction par jour, cinq fractions par semaine).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Autres tumeurs et conclusions"
        },
        {
            "text": "L'hypofractionnement, s'il est tentant dans le contexte de la pand\u00e9mie de COVID-19, ne doit pas \u00eatre prescrit en dehors des sch\u00e9mas valid\u00e9s.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Autres tumeurs et conclusions"
        },
        {
            "text": "Pour les indications pour lesquelles l'hypofractionnement est valid\u00e9 (sein, prostate, glioblastome du patient \u00e2g\u00e9, m\u00e9tastases osseuses) les recommandations existent d\u00e9j\u00e0 et doivent \u00eatre appliqu\u00e9es dans le contexte [32] . Dans les autres cas o\u00f9 il n'est pas valid\u00e9 (en raison de l'absence de niveau de preuve suffisant), il n'est pas recommand\u00e9 au risque d'\u00eatre responsable d'une toxicit\u00e9 tardive inattendue. Dans cette derni\u00e8re situation, il est pr\u00e9f\u00e9rable de d\u00e9caler les traitements non urgents, de les annuler quand il s'agit d'indications optionnelles, ou d'appliquer les sch\u00e9mas standard [33] .",
            "cite_spans": [
                {
                    "start": 214,
                    "end": 218,
                    "text": "[32]",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 592,
                    "end": 596,
                    "text": "[33]",
                    "ref_id": "BIBREF32"
                }
            ],
            "ref_spans": [],
            "section": "Autres tumeurs et conclusions"
        },
        {
            "text": "Les auteurs d\u00e9clarent l'absence de conflit d'int\u00e9r\u00eats sur cette th\u00e9matique.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conflit d'int\u00e9r\u00eats"
        },
        {
            "text": "DA : conception de l'\u00e9tude, \u00e9laboration de la m\u00e9thodologie, suivi du projet, ressources, logiciel, supervision, validation, repr\u00e9sentation des travaux, r\u00e9daction du manuscrit initial, relecture et r\u00e9vision du manuscrit.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Contribution des auteurs"
        },
        {
            "text": "CH, PG : conception de l'\u00e9tude, \u00e9laboration de la m\u00e9thodologie, suivi du projet, ressources, logiciel, supervision, validation, repr\u00e9sentation des travaux, relecture et r\u00e9vision du manuscrit.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Contribution des auteurs"
        },
        {
            "text": "Ce travail a b\u00e9n\u00e9fici\u00e9 du soutien financier et logistique du programme \u00ab radiobiologie \u00bb du Site de recherche int\u00e9gr\u00e9e sur le cancer (Siric) Montpellier Cancer : grant INCa_Inserm_DGOS_12553.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Financement"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "J"
                    ],
                    "last": "Slevin",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Hendry",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Roberts",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Agren-Cronqvist",
                    "suffix": ""
                }
            ],
            "year": 1992,
            "venue": "Radiother Oncol",
            "volume": "24",
            "issn": "",
            "pages": "215--235",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Bourgier",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Lacombe",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mang\u00e9",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "P\u00e8legrin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ozsahin",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Azria",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Crit Rev Oncol Hematol",
            "volume": "93",
            "issn": "",
            "pages": "312--321",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Practical methods for compensating for missed treatment days in radiotherapy, with particular reference to head and neck schedules",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Dale",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Hendry",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Jones",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "G"
                    ],
                    "last": "Robertson",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Deehan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Sinclair",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Clin Oncol (R Coll Radiol)",
            "volume": "14",
            "issn": "",
            "pages": "382--93",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Radiation therapy in a time of disaster",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "S"
                    ],
                    "last": "Yom",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "Zietman",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Int J Radiat Oncol Biol Phy",
            "volume": "100",
            "issn": "",
            "pages": "832--833",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Non-small cell lung tumors repopulate rapidly during radiation therapy",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "F"
                    ],
                    "last": "Fowler",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Chappell",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Int J Radiat Oncol Biol Phys",
            "volume": "46",
            "issn": "",
            "pages": "516--523",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Dose equivalents of tumour repopulation during radiotherapy: the potential for confusion",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Dale",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Jones",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Sinclair",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Br J Radiol",
            "volume": "73",
            "issn": "",
            "pages": "892--896",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature",
            "authors": [
                {
                    "first": "Gonzalez",
                    "middle": [],
                    "last": "Ferreira",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Jaen",
                    "middle": [],
                    "last": "Olasolo",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Azinovic",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Jeremic",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Rep Pract Oncol Radiother",
            "volume": "20",
            "issn": "",
            "pages": "328--367",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Van Leeuwen",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "Oei",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Crezee",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Bel",
                    "suffix": ""
                },
                {
                    "first": "Nap",
                    "middle": [],
                    "last": "Franken",
                    "suffix": ""
                },
                {
                    "first": "Lja",
                    "middle": [],
                    "last": "Stalpers",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Radiat Oncol",
            "volume": "13",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Cox",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "F"
                    ],
                    "last": "Pajak",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Asbell",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "H"
                    ],
                    "last": "Russell",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Pederson",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "W"
                    ],
                    "last": "Byhardt",
                    "suffix": ""
                }
            ],
            "year": 1993,
            "venue": "Int J Radiat Oncol Biol Phys",
            "volume": "27",
            "issn": "",
            "pages": "493--501",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Topkan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Ozdemir",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Kucuk",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Besen",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Mertsoylu",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sezer",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "PLoS One",
            "volume": "14",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Machtay",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Hsu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Komaki",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "T"
                    ],
                    "last": "Sause",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Swann",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Langer",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Int J Radiat Oncol Biol Phys",
            "volume": "63",
            "issn": "",
            "pages": "667--71",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "De Ruysscher",
                    "suffix": ""
                },
                {
                    "first": "Pijls-Johannesma",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Bentzen",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Minken",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wanders",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Lutgens",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "J Clin Oncol",
            "volume": "24",
            "issn": "",
            "pages": "1057--63",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Dose escalation for non-small cell lung cancer: analysis and modelling of published literature",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Partridge",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ramos",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sardaro",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Brada",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Radiother Oncol",
            "volume": "99",
            "issn": "",
            "pages": "6--11",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Chemoradiotherapy of locally-advanced non-small cell lung cancer: Analysis of radiation dose-response, chemotherapy and survival-limiting toxicity effects indicates a low alpha/beta ratio",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Nix",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "G"
                    ],
                    "last": "Rowbottom",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Vivekanandan",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Hawkins",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Fenwick",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Radiother Oncol",
            "volume": "143",
            "issn": "",
            "pages": "58--65",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Estimation of the alpha/beta ratio of non-small cell lung cancer treated with stereotactic body radiotherapy",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "J"
                    ],
                    "last": "Klement",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Sonke",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Allgauer",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Andratschke",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Appold",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Belderbos",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Radiother Oncol",
            "volume": "142",
            "issn": "",
            "pages": "210--216",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Hendry",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Bentzen",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Dale",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "F"
                    ],
                    "last": "Fowler",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "E"
                    ],
                    "last": "Wheldon",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Jones",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Clin Oncol (R Coll Radiol)",
            "volume": "8",
            "issn": "",
            "pages": "297--307",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "A"
                    ],
                    "last": "Perez",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "W"
                    ],
                    "last": "Grigsby",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Castro-Vita",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Lockett",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "Int J Radiat Oncol Biol Phys",
            "volume": "32",
            "issn": "",
            "pages": "1275--88",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Data-derived treatment duration goal for cervical cancer: should 8 weeks remain the target in the era of concurrent chemoradiation?",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Hong",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Foote",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Broadwater",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Sosa",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Gaillard",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "J"
                    ],
                    "last": "Havrilesky",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "JCO Clin Cancer Inform",
            "volume": "1",
            "issn": "",
            "pages": "1--15",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation?",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "R"
                    ],
                    "last": "Trott",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Kummermehr",
                    "suffix": ""
                }
            ],
            "year": 1985,
            "venue": "Radiother Oncol",
            "volume": "3",
            "issn": "",
            "pages": "1--9",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Is alpha/beta for breast cancer really low?",
            "authors": [
                {
                    "first": "X",
                    "middle": [
                        "S"
                    ],
                    "last": "Qi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "White",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "A"
                    ],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Radiother Oncol",
            "volume": "100",
            "issn": "",
            "pages": "282--290",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "L"
                    ],
                    "last": "Hershman",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Mcbride",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Jacobson",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "R"
                    ],
                    "last": "Grann",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "I"
                    ],
                    "last": "Neugut",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Int J Radiat Oncol Biol Phys",
            "volume": "65",
            "issn": "",
            "pages": "1353--60",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Time to adjuvant radiotherapy in breast cancer affects survival: implications for the American College of Surgeons Commission on Cancer Quality Metrics",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Zheleva",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Nelson",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Dumitra",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "L"
                    ],
                    "last": "Vora",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "L"
                    ],
                    "last": "Lai",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Ann Surg Oncol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1245/s10434-020-08326-8"
                ]
            }
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: results of the French Adjuvant Study Group",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Benchalal",
                    "suffix": ""
                },
                {
                    "first": "Le",
                    "middle": [],
                    "last": "Pris\u00e9",
                    "suffix": ""
                },
                {
                    "first": "\u00c9",
                    "middle": [],
                    "last": "De Lafontan",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Berton-Rigaud",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Belkac\u00e9mi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Romestaing",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Cancer",
            "volume": "104",
            "issn": "",
            "pages": "240--50",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Azria",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Belkac\u00e9mi",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Romieu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Gourgou",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gutowski",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Zaman",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Lancet Oncol",
            "volume": "11",
            "issn": "",
            "pages": "258--65",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "E"
                    ],
                    "last": "Harris",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "J"
                    ],
                    "last": "Christensen",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "T"
                    ],
                    "last": "Hwang",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Fox",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "J"
                    ],
                    "last": "Solin",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Clin Oncol",
            "volume": "23",
            "issn": "",
            "pages": "11--17",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "J"
                    ],
                    "last": "Pierce",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "F"
                    ],
                    "last": "Hutchins",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Green",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "L"
                    ],
                    "last": "Lew",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Gralow",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "B"
                    ],
                    "last": "Livingston",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Clin Oncol",
            "volume": "23",
            "issn": "",
            "pages": "24--33",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "What is the T(pot) for prostate cancer? Radiobiological implications of the equivalent outcome with (125)I or (103)Pd",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "R"
                    ],
                    "last": "King",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Int J Radiat Oncol Biol Phys",
            "volume": "47",
            "issn": "",
            "pages": "1165--1172",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Role of overall treatment time in the management of prostate cancer patients: how to manage unscheduled treatment interruptions",
            "authors": [
                {
                    "first": "H",
                    "middle": [
                        "M"
                    ],
                    "last": "Sandler",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Int J Radiat Oncol Biol Phys",
            "volume": "100",
            "issn": "",
            "pages": "841--842",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "G"
                    ],
                    "last": "Zaorsky",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "M"
                    ],
                    "last": "Churilla",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Viterbo",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Sobczak",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J Med Imaging Radiat Oncol",
            "volume": "62",
            "issn": "",
            "pages": "116--121",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between",
            "authors": [
                {
                    "first": "H",
                    "middle": [
                        "D"
                    ],
                    "last": "Thames",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Kuban",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "B"
                    ],
                    "last": "Levy",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Horwitz",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Kupelian",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Martinez",
                    "suffix": ""
                }
            ],
            "year": 1987,
            "venue": "Radiother Oncol",
            "volume": "96",
            "issn": "",
            "pages": "6--12",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "S"
                    ],
                    "last": "Bese",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hendry",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Jeremic",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Int J Radiat Oncol Biol Phys",
            "volume": "68",
            "issn": "",
            "pages": "654--61",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Guidelines for external radiotherapy and brachytherapy: 2nd edition",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Mah\u00e9",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Barillot",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Chauvet",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Cancer Radiother",
            "volume": "20",
            "issn": "",
            "pages": "4--7",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "\u00c9pid\u00e9mie de COVID-19 : recommandations \u00e0 l'usage des professionnels de l'oncologie radioth\u00e9rapie",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Giraud",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Monpetit",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Lisbona",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Chargari",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Marchesi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Didonn\u00e9",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cancer Radiother",
            "volume": "24",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.canrad.2020.03.007"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "la dose totale physique (DTP) ; \uf0b7 le facteur d'efficacit\u00e9 relative (FER) ; \uf0b7 le facteur de repopulation (FR). La formule \u00e0 utiliser est : = \u00d7 \u2212 La dose totale physique correspond au produit du nombre de fractions (n) par la dose par fraction (d) : = \u00d7",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Pour un patient qui doit recevoir 70 Gy en 35 fractions de 2 Gy du lundi au vendredi, l'\u00e9talement th\u00e9orique est de 46 jours. La dose biologique \u00e9quivalente th\u00e9orique des tissus sains (K=0) est : biologique \u00e9quivalente th\u00e9orique de la tumeur est : 10 = 35 \u00d7 2 \u00d7 (1 + 2 10 ) \u2212 0,9 \u00d7 (46 \u2212 28) = 84 \u2212 16,2 = 67,8 Gy 10 .",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "apr\u00e8s l'interruption correspond \u00e0 la dose tumorale qu'il reste \u00e0 donner avec une dose par fraction \u00ab d \u00bb sur les 20 fractions manquantes :Le facteur de repopulation tumorale correspond la repopulation tumorale potentielle en consid\u00e9rant que l'\u00e9talement a \u00e9t\u00e9 rallong\u00e9 de 14 jours, soit T = 46 j th\u00e9oriques + 14 j d'interruption (qui correspond \u00e9galement \u00e0 la dur\u00e9e suppl\u00e9mentaire \u00e0 faire), soit 60 jours.Ainsi, l'\u00e9quation suivante permettra de trouver la dose par fraction \u00ab d \u00bb en consid\u00e9rant que la dose totale optimale est celle calcul\u00e9e initialement en l'absence d'interruption (Cette \u00e9quation de second degr\u00e9 est sous la forme a 2 + b + c = 0, avec pour cet exemple : a = 1 ; b = 10 ; c = -30,3. Sa r\u00e9solution n\u00e9cessite le calcul du discriminant, \u0394.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "La seule solution positive de \u00ab d \u00bb issue du polyn\u00f4me du second degr\u00e9 est 2,44 Gy.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "quantifier le temps de traitement th\u00e9orique restant \u00e0 faire (correspond au temps exact d'arr\u00eat) ; \uf0b7 quantifier le nombre de fractions qui restent \u00e0 d\u00e9livrer ; \uf0b7 calculer les doses biologiques \u00e9quivalentes pour la tumeur consid\u00e9r\u00e9e et les tissus sains environnants selon les formules ci-dessus ; \uf0b7 quantifier l'intervalle de temps entre le jour du d\u00e9but et le jour d'interruption inclus afin de comparer ce d\u00e9lai au d\u00e9lai th\u00e9orique de prolongation pour la tumeur consid\u00e9r\u00e9e (Tprolong). Les valeurs connues pour certaines tumeurs sont d\u00e9taill\u00e9es dans le paragraphe suivant ; \uf0b7 quantifier les doses biologiques \u00e9quivalentes \u00ab restantes \u00bb des tissus sains et de la tumeur encore \u00e0 d\u00e9livrer afin de trouver un compromis dosim\u00e9trique th\u00e9orique du fait des \u00ab extra-doses \u00bb rajout\u00e9es \u00e0 la reprise. Il est important de comprendre qu'il s'agit de calculs th\u00e9oriques, se basant sur des donn\u00e9es cliniques fragmentaires le plus souvent. Toute modification du protocole de traitement, et en particulier une",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Pour la tumeur, la dose par fraction de compensation est de 2,44 Gy, \u00e0 appliquer aux 20 fractions restantes.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "Les auteurs remercient le site de recherche int\u00e9gr\u00e9e sur le cancer (Siric) Montpellier Cancer pour leur soutien financier et logistique.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Remerciements"
        }
    ]
}